PA
CGEM icon

Perceptive Advisors’s Cullinan Oncology CGEM Stock Holding History

Perceptive Advisors’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-80,100
Closed -$606K – 90
2025
Q1 		$606K Buy
+80,100
New +$769K 0.02% 80
2024
Q3 		– Sell
-749,916
Closed -$13.1M – 112
2024
Q2 		$13.1M Buy
+749,916
New +$16M 0.32% 63

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Perceptive Advisors's CGEM Position: Q2 2025 in Review

Perceptive Advisors sold out of Cullinan Oncology (CGEM) in Q2 2025, closing a stake of 80,100 shares — an estimated $606K sold.

Perceptive Advisors first reported a position in CGEM in Q2 2024 and held it in 2 quarters. The position peaked at $13.1M in Q2 2024. 143 funds tracked by Wall St. Rank hold CGEM as of Q2 2025.

  • Perceptive Advisors reported no remaining Cullinan Oncology position as of Q2 2025 after selling out during the quarter.
  • Perceptive Advisors sold 80,100 Cullinan Oncology shares in Q2 2025, an estimated $606K.
  • Perceptive Advisors first reported a position in Cullinan Oncology in Q2 2024 and held it in 2 quarters.
  • Perceptive Advisors's Cullinan Oncology position peaked at $13.1M in Q2 2024.
  • 143 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2025.

Based on Perceptive Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.